Table 8.
Association of PD-L1 staining with estrogen receptor/progesterone receptor-positive and triple-negative status in sTIL subgroups in patients with neoadjuvant chemotherapy
| TC | TCIC | IC | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| sTIL < 10% | sTIL ≥10% | sTIL < 10% | sTIL ≥10% | sTIL < 10% | sTIL ≥10% | |||||||
| PD-L1 | Neg | Pos | Neg | Pos | Neg | Pos | Neg | Pos | Neg | Pos | Neg | Pos |
| ER/PR pos | 77 | 0 | 13 | 3 | 70 | 2 | 9 | 6 | 70 | 2 | 10 | 5 |
| TNBC | 16 | 3 | 10 | 6 | 11 | 7 | 6 | 8 | 12 | 6 | 9 | 5 |
| Fisher P value | 0.0068 | 0.4331 | 0.0001 | 0.4661 | 0.0006 | 1 | ||||||
ER estrogen receptor, PR progesterone receptor, TNBC triple-negative breast cancer, sTIL stromal tumor infiltrating lymphocytes, pos positive, neg negative